Skip to main content
TipRanks
Go Ultimate75% OFF

Teleflex (TBH) AI Stock Analysis

0 Followers
CH:TBH

Teleflex

(BX Swiss:TBH)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring Procedure-Driven DemandTeleflex benefits from recurring consumable demand tied to routine and complex hospital procedures. This replenishment-based model can support durable revenue visibility, while broad clinical applications and hospital formularies provide opportunities to deepen utilization across healthcare systems.
Negative Factors
Revenue and Profitability DeteriorationRecent contraction in revenue and volatile profitability weaken the earnings base and make performance less predictable. Although gross margins remain stable, sustained recovery depends on restoring growth and converting product economics into consistent operating earnings across the portfolio.

Teleflex Business Overview & Revenue Model

Company Description

Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within cri...

Teleflex Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was predominantly positive. Teleflex delivered better-than-expected third-quarter EPS, expanded margins, reduced leverage, completed significant share repurchases, maintained its revenue outlook, and raised full-year EPS guidance. The company also reported progress on the Interventional integration, organizational transformation, innovation programs, and planned cost savings. These positives were tempered by continued Interventional integration disruption, uncertainty around the timing of the Acute Care and Interventional Urology divestiture, ongoing tariff exposure, near-term R&D and investment-related margin pressure, and the gradual ramp expected for EZPLAZ.

Positive Updates

Strong Third-Quarter Financial Performance
Teleflex reported third-quarter revenue of $567.8 million, up 0.2% year-over-year on a GAAP basis and up 3.0% on a pro forma adjusted constant currency basis. Adjusted operating margin was 25%, up 300 basis points year-over-year, while adjusted earnings per share was $2.63, an increase of 39.2% year-over-year and ahead of expectations.

Negative Updates

Interventional Growth Still Constrained by Integration Disruption
Interventional revenue growth was only 0.2% year-over-year because of ongoing integration and restructuring activities associated with the Vascular Intervention acquisition. Management said the integration has taken longer than originally planned and that additional work remains across customer ordering, distributor transitions, consignment processes, and sales force productivity.

Company Guidance

Teleflex continues to expect 2026 pro forma adjusted constant currency revenue growth in the range of 3.5% to 4.5% and raised adjusted EPS guidance to $7.50 to $7.75 from $6.90 to $7.20, including a $0.31 benefit from IEEPA tariff refunds; foreign exchange is now expected to be approximately $9 million to $10 million benefit to reported revenue, adjusted operating margin approximately 20%, net interest expense approximately $85 million, adjusted tax rate approximately 11.5%, and shares outstanding approximately 42.5 million. Once the Acute Care and Interventional Urology divestiture closes, operating margin is expected to approximate 23% in year 1, while the divestiture is targeted to close by year-end but could extend into 2027; the multiyear restructuring plan is expected to achieve approximately $50 million in annual pretax cost savings upon completion in mid-2028. Interventional is targeting a modest sequential improvement quarter-over-quarter, with mid-single-digit end markets, and EZPLAZ revenue is expected to be immaterial in 2026, become a contributor in 2027, and have a modest revenue ramp over the first several years against a potential U.S. market opportunity of at least $200 million; tariffs are currently approximately a little over $30 million and expected to be similar for 2027.

Teleflex Risk Analysis

Teleflex disclosed 34 risk factors in its most recent earnings report. Teleflex reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.We could be adversely affected by our ongoing CEO transition.Q4, 2025
2.The strategic transformation that we are currently implementing may not have the intended results and may be harmful to our business.Q4, 2025

Teleflex Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:TBH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MMSIMMSI71Outperform$5.06B31.359.65%―9.34%33.77%
ICUIICUI64Neutral$4.40B71.582.81%―-5.82%―
BDXBDX63Neutral$57.93B51.274.64%1.87%-7.40%-28.89%
BAXBAX53Neutral$13.14B-18.40-11.62%0.16%5.33%-164.67%
ANGOANGO52Neutral$452.51M-13.68-19.25%―8.20%-0.88%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%ANGOBAXBDXICUIMMSIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:TBH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ANGOAngiodynamics, Inc.10.81-1.49-12.11%
BAXBaxter International Inc25.397.2539.93%
BDXBecton, Dickinson and Co212.7866.3845.34%
ICUIICU Medical172.5223.9816.14%
MMSIMerit Medical84.34-2.83-3.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.